Navigation Links
Omeros Appoints New Vice President of Clinical Development
Date:8/5/2009

SEATTLE, Aug. 5 /PRNewswire/ -- Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros' PharmacoSurgery(TM) product candidates. These include OMS103HP, the Company's lead candidate being evaluated in a Phase 3 clinical program for improved joint function and pain reduction following arthroscopic surgery, OMS302 in a Phase 2 program for use in cataract surgery, and OMS201 in a Phase 1/2 program for use in uroendoscopy.

"Dr. Murray brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small pharmaceutical companies," said Gregory A. Demopulos, M.D., Chairman & CEO of Omeros. "Dr. Murray will work closely with our team members to continue building the long-term value of Omeros and our products."

"Omeros is poised to deliver important new treatments to patients through its PharmacoSurgery platform," said Dr. Murray. "In addition, we have several preclinical central nervous system and inflammation programs that have the potential to address significant unmet medical needs. This is an important time for Omeros and I'm excited to play a role here."

Prior to Omeros, Dr. Murray served in various positions, most recently as Chief Medical Officer at Memory Pharmaceuticals, a biopharmaceutical company that developed treatments for central nervous system disorders and was acquired by Hoffman-La Roche Inc. in January 2009. Before that, Dr. Murray held various positions at Pfizer Global Pharmaceuticals, including senior medical director and therapeutic team leader for schizophrenia. Dr. Murray received his M.D. and Ph.D. in molecular and cellular biology from the Medical University of South Carol
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
2. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
5. Omeros Appoints David A. Mann to its Board of Directors
6. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
9. Brookstone Pharmaceuticals Appoints New Corporate Position
10. PDI Appoints Gerald P. Belle as Lead Independent Director
11. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... 23, 2014 The report ... as its definition, classification, application and industry ... manufacturing process, and product cost structure. Production ... The analysis also covers upstream raw materials, ... development trend and proposals. In the end, ...
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Gene arrays are solid supports upon which a , ... have been placed at , ... array analysis, a nucleic acid-containing sample is labeled , ... on the array. (In the literature, the term ...
... Ambion has developed a system for , ... on in vitro , transcription, ... (patent pending). This kit produces transfection-ready siRNA , ... researchers at the Salk Institute describe the successful , ...
... The Silencer siRNA , ... column purification to prepare transfection-ready siRNAs. With , ... is one example of how siRNAs prepared by the , ... in gene silencing studies. , ...
Cached Biology Technology:Array Analysis: The Basics 2Array Analysis: The Basics 3Array Analysis: The Basics 4Array Analysis: The Basics 5Your Data: Silencing Neural Cell Adhesion Genes with In Vitro Transcribed siRNAs 2Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs 2
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need ... your password, site key or the answer to your secret ... teacher? Today, Hoyos Labs , a ... will finally put an end to the frustration that comes ... . 1U leverages a user,s smartphone to acquire his or ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... This release is available in German . ... and know-how in micro- and nanotechnologies for users from ... by KIT is starting operation: Ten leading institutions from ... available a total of 36 high-tech installations along with ...
... most invasive plants introduced to the U.S. from Europe and ... the natives. A new study indicates that eventually, however, its ... becomes less potent. The study, in Proceedings ... the first to show that evolutionary forces can alter the ...
... Institute at Oregon State University suggests that some natural food ... prevent cancer, may be able to play a more significant ... drugs that are now used in chemotherapy. A new ... examined the activity of chlorophyllin and found that, on ...
Cached Biology News:Scientific pathways into the nanoworld 2Scientific pathways into the nanoworld 3Over time, an invasive plant loses its toxic edge 2Over time, an invasive plant loses its toxic edge 3Natural compounds, chemotherapeutic drugs may become partners in cancer therapy 2Natural compounds, chemotherapeutic drugs may become partners in cancer therapy 3